Shionogi & Co Ltd

Common Name
Shionogi & Co
Country
Japan
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
4,955
Ticker
4507
Exchange
TOKYO STOCK EXCHANGE
Description
Shionogi & Co., Ltd. is a leading pharmaceutical company specializing in the research, development, and distribution of pharmaceutical products. Established in Japan in 1878, Shionogi focuses primaril...

Financial Statements of Shionogi & Co

Below are the financial statements of Shionogi & Co, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

All figures in billions of JPY20242023
Revenue
410.07a
426.68a
Profit from license transfer
25.01a
0a
Cost of sales
-57.6a
-62.25a
Gross profit
377.48a
364.44a
Selling, general and administrative expenses
-99.65a
-97.78a
Research and development expenses
-102.64a
-102.39a
Amortization of intangible assets associated with products
-3.73a
-3.72a
Other income
6.19a
3.9a
Other expenses
-24.34a
-15.45a
Operating profit
153.31a
149a
Finance income
51.67a
75.83a
Finance costs
-6.7a
-4.5a
Profit before tax
198.28a
220.33a
Income tax expense
-37.71a
-35.84a
Profit
160.58a
184.5a
Profit attributable to
Owners of parent
162.03a
184.97a
Non-controlling interests
-1.46a
-0.47a

Verified Sources Behind Shionogi & Co’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Shionogi & Co’s data sources below and access millions more through our Disclosure Search.

a. Shionogi & Co's Integrated Report 2024
Trace every data point back to Shionogi & Co’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?